CN101444539B - 绵羊副痘病毒毒株抗器官纤维化的用途 - Google Patents

绵羊副痘病毒毒株抗器官纤维化的用途 Download PDF

Info

Publication number
CN101444539B
CN101444539B CN200810149856.XA CN200810149856A CN101444539B CN 101444539 B CN101444539 B CN 101444539B CN 200810149856 A CN200810149856 A CN 200810149856A CN 101444539 B CN101444539 B CN 101444539B
Authority
CN
China
Prior art keywords
fibrosis
animal
purposes
liver
strains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN200810149856.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN101444539A (zh
Inventor
C·希尔斯-迪特里希
T·施拉普
A·西林
A·克诺尔
O·维伯
G·泰斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aicuris GmbH and Co KG
Original Assignee
Aicuris GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris GmbH and Co KG filed Critical Aicuris GmbH and Co KG
Publication of CN101444539A publication Critical patent/CN101444539A/zh
Application granted granted Critical
Publication of CN101444539B publication Critical patent/CN101444539B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24261—Methods of inactivation or attenuation
    • C12N2710/24264—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Addiction (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN200810149856.XA 2000-07-11 2001-07-11 绵羊副痘病毒毒株抗器官纤维化的用途 Expired - Lifetime CN101444539B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10033581.0 2000-07-11
DE10033581 2000-07-11
DE10122233A DE10122233A1 (de) 2000-07-11 2001-05-08 Verwendung von Stämmen des Parapoxvirus ovis gegen Organfibrosen
DE10122233.5 2001-05-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN018151272A Division CN1452496B (zh) 2000-07-11 2001-07-11 绵羊副痘病毒毒株抗器官纤维化的用途

Publications (2)

Publication Number Publication Date
CN101444539A CN101444539A (zh) 2009-06-03
CN101444539B true CN101444539B (zh) 2016-07-06

Family

ID=7648485

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200810149856.XA Expired - Lifetime CN101444539B (zh) 2000-07-11 2001-07-11 绵羊副痘病毒毒株抗器官纤维化的用途

Country Status (14)

Country Link
JP (2) JP5587950B2 (ko)
KR (1) KR100845643B1 (ko)
CN (1) CN101444539B (ko)
AT (1) ATE445413T1 (ko)
BR (1) BRPI0112411B8 (ko)
DE (2) DE10122233A1 (ko)
DK (1) DK1303302T3 (ko)
DO (1) DOP2001000210A (ko)
EC (1) ECSP034420A (ko)
ES (1) ES2332355T3 (ko)
PE (1) PE20020218A1 (ko)
PT (1) PT1303302E (ko)
SV (1) SV2002000527A (ko)
ZA (1) ZA200300276B (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102015111756A1 (de) * 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Rekombinanter Orf-Virus-Vektor
US11077157B2 (en) 2016-02-16 2021-08-03 Osaka University Medicinal composition for treating fibrosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1142187A (zh) * 1994-02-23 1997-02-05 安东·迈耶 基于痘病毒成分结合体的拟免疫诱导体，其制备方法和其作为药物的应用
CN1215996A (zh) * 1996-04-15 1999-05-05 安东·迈耶 减毒的非免疫原性痘病毒和副痘病毒衍生的多功能副痘病毒免疫诱导剂用作药物的新适应症

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1142187A (zh) * 1994-02-23 1997-02-05 安东·迈耶 基于痘病毒成分结合体的拟免疫诱导体，其制备方法和其作为药物的应用
CN1215996A (zh) * 1996-04-15 1999-05-05 安东·迈耶 减毒的非免疫原性痘病毒和副痘病毒衍生的多功能副痘病毒免疫诱导剂用作药物的新适应症

Also Published As

Publication number Publication date
CN101444539A (zh) 2009-06-03
ZA200300276B (en) 2004-04-13
DE50115181D1 (de) 2009-11-26
JP5587950B2 (ja) 2014-09-10
BR0112411A (pt) 2003-05-27
ECSP034420A (es) 2003-03-10
PE20020218A1 (es) 2002-05-19
KR100845643B1 (ko) 2008-07-10
BRPI0112411B8 (pt) 2021-05-25
SV2002000527A (es) 2002-10-24
DK1303302T3 (da) 2010-02-08
JP2014196329A (ja) 2014-10-16
DE10122233A1 (de) 2002-01-24
DOP2001000210A (es) 2002-12-15
ES2332355T3 (es) 2010-02-03
ATE445413T1 (de) 2009-10-15
KR20030019562A (ko) 2003-03-06
JP5950964B2 (ja) 2016-07-13
JP2012214492A (ja) 2012-11-08
PT1303302E (pt) 2009-11-11
BRPI0112411B1 (pt) 2018-02-27

Similar Documents

Publication Publication Date Title
Grimley et al. Specific membranous structures associated with the replication of group A arboviruses
US20140105928A1 (en) Antiviral and antibacterial activity from medicinal mushrooms
Pan et al. Aqueous extract from a Chaga medicinal mushroom, Inonotus obliquus (higher basidiomyetes), prevents herpes simplex virus entry through inhibition of viral-induced membrane fusion
NZ537255A (en) Administration of therapeutic viruses
TW202042828A (zh) 抑制病毒感染的方法及組合物
CN1452496B (zh) 绵羊副痘病毒毒株抗器官纤维化的用途
CN101444539B (zh) 绵羊副痘病毒毒株抗器官纤维化的用途
Gallardo-Romero et al. Use of live Variola virus to determine whether CAST/EiJ mice are a suitable surrogate animal model for human smallpox
Valdés et al. Chromatographic removal combined with heat, acid and chaotropic inactivation of four model viruses
Weissenbacher et al. Sensitivity of human conjunctival tissue cultures to adenovirus 8, herpes simplex and vaccinia viruses. Induction of resistance by an interferon inducer
Amos et al. Inhibition of influenza virus synthesis by 2-thiouracil
Kitamura et al. Studies on a heat-labile variola virus inhibitor in normal sera. I. Detection by the variola focus reduction assay and its general characteristics
CN114990079B (zh) 治疗性缺陷干扰颗粒及其在制备用于防治rsv病毒感染的产品中的应用
Barban et al. Differential inhibitory effects of interferon on deoxythymidine kinase induction of vaccinia-infected cell cultures
CN115414366B (zh) 11-酮基-beta-乳香酸在制备治疗猫杯状病毒病的药物中的应用
CN118526483A (zh) 一种天然植物来源的联苯多酚化合物在制备治疗疱疹性疾病的药物中的应用
Heremans et al. Interferon production and virus replication in lymphoblastoid cells infected with different viruses
CN117899103A (zh) 铁线莲多糖在制备治疗或预防hcmv药物中的应用
CN117942350A (zh) 桑叶多糖在制备治疗或预防hcmv药物中的应用
Oie et al. Studies on reovirus type 2: viral interference with UV-inactived virus
JPH0567611B2 (ko)
CN116350773A (zh) 手足口病疫苗及其制备方法和应用
CN115851619A (zh) 二甲双胍在抑制vsv细胞复制中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20160706